{
    "clinical_study": {
        "@rank": "164739", 
        "arm_group": [
            {
                "arm_group_label": "combination iodine 125 seed implants", 
                "description": "30 cases should be treated with iodine 125 seed implants  0.5 mc transperineal  prostate implant +Zoladex 3.6mg im 1/28d  (LHRH agonist, 3.6mg subcutaneous injection 1/4weeks)."
            }, 
            {
                "arm_group_label": "LHRH agonists", 
                "description": "30 cases should be treated with Zoladex 3.6mg im 1/28d  (LHRH agonist, 3.6mg subcutaneous injection 1/4weeks)."
            }
        ], 
        "brief_summary": {
            "textblock": "Patients with prostate cancer should have the following examination including biopsy, serum\n      PSA volume, prostate CT scan or MRI, bone scan, abdomen ultrasound, chest X ray, blood\n      biochemistry, blood rout, ECG and testosterone.\n\n      Two groups:\n\n      First group:30 cases should be treated with iodine 125 seed implants  0.5 mc transperineal\n      prostate implant +Zoladex 3.6mg im 1/28d  (LHRH agonist, 3.6mg subcutaneous injection\n      1/4weeks).\n\n      Second group: 30 cases should be treated with Zoladex 3.6mg im 1/28d  (LHRH agonist, 3.6mg\n      subcutaneous injection 1/4weeks).\n\n      PFS and PSA level will be the primary variables."
        }, 
        "brief_title": "Combination Iodine 125 Seed Implants and LHRH Agonists for Locally Advanced (Stage T3) Prostate Cancer", 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Provision of written informed consent\n\n          2. T2c-T3b N0  M0  (biopsy\u3001 bone scan\u3001 CT\u3001 MRI)\n\n          3. No  Metastasis (bone scan\u3001 CT\u3001 MRI)\n\n          4. PSA level>10ng/ml\n\n          5. Histological or cytological confirmation of prostate cancer\n\n          6. Able to understand and comply with the requirements of the study\n\n        Exclusion Criteria:\n\n          1. Having been treated with external radiation therapy or chemistry  therapy.\n\n          2. Clinical relevant disease and/or abnormalities (past or present), eg, significant\n             cardiovascular, renal or liver disease, malignancy, gastro-intestinal disorders, or\n             other conditions which could affect the absorption/elimination of drugs.\n\n          3. Alanine amino transferase (ALT) or aspartate amino transferase (AST) greater than 2\n             times the upper limit of normal (ULN) at screening findings that make it undesirable\n             for the patient to participate in the study in the opinion of the investigator(s)\n\n          4. In the opinion of the investigator(s), any evidence of severe or uncontrolled\n             systemic disease (eg, currently unstable or unresolved respiratory, cardiac, hepatic,\n             or renal disease).\n\n          5. Contra-indications (eg, known or suspected allergy) to GnRH antagonists or\n             excipients(non-active ingredients of investigational product).\n\n          6. Treatment with a non-approved or investigational drug within 30 days before study\n             entry.\n\n          7. Bibulosity or drug abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Subject number: <<60>>"
            }
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01813097", 
            "org_study_id": "D8664C00011"
        }, 
        "intervention_browse": {
            "mesh_term": "Iodine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "To detective the effect of the treatment of combination iodine 125 seed implants and LHRH agonists for the patients with locally advanced prostate cancer.", 
        "lastchanged_date": "March 15, 2013", 
        "number_of_groups": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "To detective the effect of the treatment of combination iodine 125 seed implants and LHRH agonists for the patients with locally advanced prostate cancer.", 
            "safety_issue": "Yes", 
            "time_frame": "two years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01813097"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chinese PLA General Hospital", 
            "investigator_full_name": "Xu Yong", 
            "investigator_title": "director", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Chinese PLA General Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chinese PLA General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2008", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2008"
    }
}